Somewhere around month four or five, your clinician suggests moving up a dose tier — say, the tirzepatide-class jump from 5mg to 7.5mg. Clinically it's routine. Financially, depending on your provider's billing architecture, it costs anywhere from zero to a documented near-doubling of your monthly bill. Here's the escalation priced across the market's structures.
Key Takeaways
- The same clinical decision — one dose tier up — prices at $0 on flat plans, +$30–80/month on gentle tiers, and +$170/month at known cliff structures.
- The documented cliff example in our tracker: ~$229/month jumping to $399/month at 7.5mg+ — a 74% increase at one escalation.
- Annualized, the spread between structures at higher doses runs well past $1,500/year.
- Ask one question before starting anywhere: 'Show me the complete dose-price schedule, top tier included.' The answer predicts your year-one total better than the headline price.
The Escalation, Priced Three Ways
| Billing structure | At 5mg | At 7.5mg | The increase | Year at 7.5mg |
|---|---|---|---|---|
| Flat plan ($179/mo) | $179 | $179 | $0 | $2,148 |
| Flat annual-commit ($99/mo) | $99 | $99 | $0 | $1,188 |
| Gentle tiers | $199 | $249 | +$50/mo | $2,988 |
| Cliff structure (documented example) | $229 | $399 | +$170/mo (+74%) | $4,788 |
Read the rightmost column: the identical patient on the identical dose pays between $1,188 and $4,788 for the year depending purely on billing architecture chosen months earlier.
Why Cliffs Exist
Higher doses consume more compounded product, so some price slope is defensible cost pass-through. Cliffs are something else: the low tiers are priced as acquisition bait, and the cliff sits exactly where the standard titration path — which most patients follow — will deliver them. It's not hidden, exactly; it's disclosed where marketing doesn't point. Providers with cliff structures are betting you'll price-shop the starter tier and inertia-pay the rest.
The Wrinkle: Not Everyone Escalates
Fairness requires the reverse case: if you're among the patients who respond fully at lower tiers and never climb, a tiered plan's cheap low tiers beat flat pricing — you'd be subsidizing escalations you never take. The problem is sequencing: you don't know your dose destiny at signup. Which is why the decision rule runs on information, not prediction.
The Decision Rule
- Dose unknown (new patient): flat pricing. You're buying insurance against the exact cliff you can't predict, and the standard titration path makes escalation the likely case.
- Dose known and low (proven responder or maintainer): shop tiers at your tier — and confirm step-downs are as frictionless as step-ups.
- Everyone, everywhere: obtain the full dose-price schedule in writing before the first charge. A provider reluctant to show its top tier has answered your question.
Flat-at-Every-Dose Programs We Track
Telos Rx — Tirzepatide
Compounded tirzepatide — from $49/mo on 12-month plans
$199 month-to-month sliding to $49/mo annual, flat at every dose, FSA/HSA accepted, cancel anytime.
Compounded medications are not FDA-approved.
Visit Telos Rx Paid linkTelos Rx — Semaglutide
Compounded semaglutide — from $49/mo on 12-month plans
Identical flat-at-every-dose structure on the semaglutide side.
Compounded medications are not FDA-approved.
Visit Telos Rx Paid linkEmbody
Injectable semaglutide — $149 first month
Our lead injectable pick: physician-supervised semaglutide with clean flat pricing after the intro month.
Compounded medications are not FDA-approved.
Visit Embody Paid linkVerdict: the dose increase is where GLP-1 pricing stops being a headline number and becomes an architecture. Buy the architecture, not the ad.
Affiliate disclosure: Links marked "Paid link" are affiliate links. We may earn a commission if you sign up through them, at no extra cost to you. This supports our independent research.
Compounded medication notice: Compounded medications are not FDA-approved. The FDA does not verify the safety, effectiveness, or quality of compounded drugs before they are marketed. Brand-name alternatives (Wegovy, Ozempic, Zepbound, Rybelsus) are FDA-approved.
Medical disclaimer: This article is for informational purposes only and is not medical advice. GLP-1 medications are prescription drugs. Always consult a licensed healthcare provider about diagnosis, treatment, dosing, and whether these medications are appropriate for you.